Inflammation and infections as risk factors for ischemic stroke

Stroke

Volumn 34, Issue 10, 2003, Pages 2518-2532

  Lindsberg, Perttu J ^a,c   Grau, Armin J ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KLINIKUM LUDWIGSHAFEN   (Germany)

^c Neuroscience Program   (Finland)

Author keywords

Anticholesteremic agents; Chlamydia; Human experimentation; Infection; Inflammation; Leukocytes; NF kappa B; Stroke

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BIOACCUMULATION; BRAIN BLOOD VESSEL; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHLAMYDOPHILA PNEUMONIAE; CORRELATION ANALYSIS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HELICOBACTER PYLORI; HUMAN; INFECTION; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE ACTIVATION; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOGENESIS;

BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CAUSALITY; CEREBROVASCULAR ACCIDENT; COMORBIDITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFECTION; INFLAMMATION; RISK FACTORS;

EID: 0141865574     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000089015.51603.CC     Document Type: Review

References (216)

1. Howard G, Howard VJ, Katholi C, Oli MK, Huston S. Decline in US stroke mortality: an analysis of temporal patterns by sex, race, and geographic region. Stroke. 2001;32:2213-2220.
2. Kelly-Hayes M, Wolf PA, Kase CS, Brand FN, McGuirk JM, d'Agostino RB. Temporal patterns of stroke onset: the Framingham Study. Stroke. 1995;26:1343-1347.
3. Jakovljevic D, Salomaa V, Sivenius J, Tamminen M, Sarti C, Salmi K, Kaarsalo E, Narva V, Immonen-Räihä P, Torppa J, Tuomilehto J. Seasonal variation in the occurrence of stroke in a Finnish adult population: the FINMONICA Stroke Register. Stroke. 1996;27:1774-1779.
4. Bonita R, Beaglehole R. Does treatment of hypertension explain the decline in mortality from stroke? BMJ. 1986;292:191-192.
5. Klag MJ, Whelton PK, Seidler AJ. Decline in US stroke mortality: demographic trends and antihypertensive treatment. Stroke. 1989;20:14-21.
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
7. Bradford Hill A. The environment and disease: association or causation. Proc R Soc Med. 1965;58:295-300.
8. Stary HC, Chandler AB, Glagov S, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462-2478.
9. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-2690.
10. Endres M, Laufs U, Merz H, Kaps M. Focal expression of intercellular adhesion molecule-1 in the human carotid bifurcation. Stroke. 1997;28: 77-82.
11. Perry VH, Anthony DC, Bolton SJ, Brown HC. The blood-brain barrier and the inflammatory response. Mol Med Today. 1997;3:337-341.
12. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, Hallenbeck JM. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke. 2002;33:2156-2164.
13. Andjelkovic AV, Spencer DD, Pachter JS. Visualization of chemokine binding sites on human brain microvessels. J Cell Biol. 1999;145: 403-412.
14. Stern DM, Kaiser E, Nawroth PP. Regulation of the coagulation system by vascular endothelial cells. Haemostasis. 1988;18:202-214.
15. Fassbender K, Bertsch T, Mielke O, Mühlhauser F, Hennerici M. Adhesion molecules in cerebrovascular diseases: evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease. Stroke. 1999;30:1647-1650.
16. Rohde LE, Hennekens CH, Ridker PM. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol. 1999;19:1595-1599.
17. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM. Levels of soluble adhesion molecules in patients with dyslipidemia. Circulation. 1996;93:1334-1338.
18. Ferri C, Desideri G, Valenti M, Bellini C, Pasin M, Santucci A, De Mattia G. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension. 1999;34:568-573.
19. Kawamura T, Umemura T, Kanai A, Uno T, Matsumae H, Sano T, Sakamoto N, Sakakibara T, Nakamura J, Hotta N. The incidence and characteristics of silent cerebral infarction in elderly diabetic patients: association with serum-soluble adhesion molecules. Diabetologia. 1998;41:911-917.
20. Bruunsgaard H, Skinhøj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumour necrosis factor-α (TNF-α) and atherosclerosis. Clin Exp Immunol. 2000;121:255-260.
21. Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-a plasma level in patients with type I diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med. 2000;248:67-76.
22. Wong D, Prameya R, Dorovini-Zis K. In vitro adhesion and migration of T lymphocytes across monolayers of human brain microvessel endothelial cells: regulation by ICAM-1, VCAM-1, E-selectin and PECAM-1. J Neuropathol Exp Neurol. 1999;58:138-152.
23. Rajamani K, Fisher M, Fisher M. Atherosclerosis: pathogenesis and pathophysiology. In: Ginsberg MD, Bogousslavsky J, eds. Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. Malden, Mass: Blackwell Science; 1998:308-318.
24. Lefer DJ, Granger DN. Monocyte rolling in early atherogenesis: vital role in lesion development. Circ Res. 1999;84:1353-1355.
25. Wilson SH, Caplice NM, Simari RD, Holmes DR Jr, Carlson PJ, Lerman A. Activated nuclear factor κB is present in the coronary vasculature of experimental hypercholesterolemia. Atherosclerosis. 2000;148:23-30.
26. Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens. 1994;12:925-928.
27. DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens. 1997;10:1335-1341.
28. Buemi M, Allegra A, Aloisi C, Corica F, Alonci A, Ruello A, Montalto G, Frisina N. Cold pressor test raises serum concentrations of ICAM-1, VCAM-1, and E-selectin in normotensive and hypertensive patients. Hypertension. 1997;30:845-847.
29. Porreca E, Di Febbo C, Mincione G, Reale M, Baccante G, Guglielmi MD, Cuccurullo F, Colletta G. Increased transforming growth factor-beta production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension. 1997;30:134-139.
30. Dorffel Y, Latsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmeister GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 1999;34:113-117.
31. Woodman RJ, Watts GF, Puddey IB, Burke V, Mori TA, Hodgson JM, Beilin LJ. Leukocyte count and vascular function in type 2 diabetic subjects with treated hypertension. Atherosclerosis. 2002;163:175-181.
32. Holschermann H, Terhalle HM, Zakel U, Maus U, Parviz B, Tillmans H, Haberbosch W. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives. Thromb Haemost. 1999;82:1614-1620.
33. Bergmann S, Siekmeier R, Mix CD, Jaross W. Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir Physiol. 1998;114:269-275.
34. Grau AJ, Buggle F, Becher H, Werle E, Hacke W. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Haemost. 1996;82: 245-255.
35. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-1065.
36. Hallenbeck JM, Dutka AJ, Kochanek PM, Siren A, Pezeshkpour GH, Feuerstein G. Stroke risk factors prepare rat brainstem tissues for modified local Shwartzman reaction. Stroke. 1988;19:863-869.
37. Hallenbeck JM, Dutka AJ, Vogel SN, Heldman E, Doron DA, Feuerstein G. Lipopolysaccharide-induced production of tumor necrosis factor activity in rats with and without risk factors for stroke. Brain Res. 1991;541:115-120.
38. Siren AL, Liu Y, Feuerstein G, Hallenbeck JM. Increased release of tumor necrosis factor-α into cerebrospinal fluid and peripheral circulation of aged rats. Stroke. 1993;24:880-886.
39. Virchow R. Der atheromatöse Prozess der Arterien. Wien Med Wochenschr. 1856;6:825.
40. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6:131-138.
41. van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM, Becker AE. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest. 1989;61:166-170.
42. Kaartinen M, van der Wal AC, van der Loos CM, Piek JJ, Koch KT, Becker AE, Kovanen PT. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol. 1998;32: 606-612.
43. Johnson JL, Jackson CL, Angelini GD, George SJ. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 1998;18:707-715.
44. Lehtonen-Smeds EMP, Lindsberg PJ, Soinne L, Saimanen E, Salonen O, Lassila R, Järvinen AA, Sarna S, Kaste M, Kovanen PT. High mast cell density in atherosclerotic plaques from endarterectomized carotid arteries is associated with an atherogenic serum lipid profile and cerebrovascular events: results from the Helsinki Carotid Endarterectomy Study. Stroke. 2002;33:376.
45. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
46. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 1990;344:254-257.
47. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today. 1990;11:97-101.
48. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85:1260-1266.
49. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks HL. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein I and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039-2046.
50. Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet. 2000;355:19-24.
51. van der Wal AC, Becker AE, van der Loos CM, Tigger AJ, Das PK. Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to inflammation: a concept. Coron Artery Dis. 1994;5:463-469.
52. O'Holleran LW, Kennelly MM, McClurken M, Johnson JM. Natural history of asymptomatic carotid plaque: a five year follow-up study. Am J Surg. 1987;154:659-662.
53. Avril G, Batt M, Guidoin R, Marois M, Hassen-Khodja R, Daune B, Galiardi JM, Le-Bas P. Carotid endarterectomy plaques: correlations of clinical and anatomic findings. Ann Vasc Surg. 1991;5:50-54.
54. Hatsukami TS, Ferguson MS, Beach KW, Gordon D, Detmer P, Burns D, Alpers C, Strandness DE Jr. Carotid plaque morphology and clinical events. Stroke. 1997;28:95-100.
55. Nuotio K, Lindsberg PJ, Carpén O, Soinne L, Sarna S, Saimanen E, Salonen O, Lassila R, Järvinen A, Kovanen P, Kaste M. Adhesion molecule expression in symptomatic and asymptomatic carotid stenosis: results from the Helsinki Carotid Endarterectomy Study. Neurology. 2003;60:1890-1899.
56. Sohma Y, Sasano H, Shiga R, Saeki R, Suzuki T, Nagura H, Nose M, Yamamoto T. Accumulation of plasma cells in atherosclerotic lesions of Watanabe heritable rabbits. Proc Natl Acad Sci USA. 1995;92: 4937-4941.
57. Hajjar DP. Viral pathogenesis of atherosclerosis: Warner Lambert/Parke-Davis Award lecture. Am J Pathol. 1991;139:1195-211.
58. Saikku P, Leinonen M, Mattila K, Ekman M-R, Nieminen MS, Mäkelä PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel Chlamydia, TW AR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-985.
59. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis. 2000;181:S402-S410.
60. Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ, Strandness ED, Wang SP. Chlamydia pneumoniae (TW AR) in atherosclerosis of the carotid artery. Circulation. 1995;92:3397-3400.
61. Maass M, Krause E, Engel PM, Kruger S. Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis. Angiology. 1997;48:699-706.
62. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus and atherosclerosis of the carotid artery. Circulation. 1997;96:2144-2148.
63. Yamashita K, Ouchi K, Shirai M, Gondo T, Nakazawa T, Ito H. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke. 1998;29:773-778.
64. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998;98:300-307.
65. Gibbs RG, Sian M, Mitchell AW, Greenhalgh RM, Davies AH, Carey N. Chlamydia pneumoniae does not influence atherosclerotic plaque behavior in patients with established carotid stenosis. Stroke. 2000;31: 2930-2935.
66. Ouchi K, Fujii B, Kudo S, Shirai M, Yamashita K, Gondo T, Ishihara T, Ito H, Nakazawa T. Chlamydia pneumoniae in atherosclerotic and non-atherosclerotic tissue. J Infect Dis. 2000;181(suppl 3):S441-S443.
67. LaBiche R, Koziol D, Quinn TC, Gaydos C, Azhar S, Ketron G, Sood S, DeGraba TJ. Presence of Chlamydia pneumoniae in human symptomatic and asymptomatic carotid atherosclerotic plaque. Stroke. 2001;32:855-860.
68. Dobrilovic N, Vadlamani L, Meyer M, Wright CB. Chlamydia pneumoniae in atherosclerotic carotid artery plaques: high prevalence among heavy smokers. Am Surg. 2001;67:589-593.
69. Ong GM, Coyle PV, Barros D'Sa AA, McCluggage WG, Duprex WP, O'Neil HJ, Wyatt DE, Bamford KB, O'Louglin B, McCaughey C. Non-detection of Chlamydia species in carotid atheroma using gene primers by nested PCR in a population with a high prevalence of Chlamydia pneumoniae antibody. BMC Infect Dis. 2001;1:12.
70. Paterson DL, Hall J, Rasmussen SJ, Timms P. Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. Pathology. 1998;30:169-172.
71. Virok D, Kis Z, Karai L, Intzedy L, Burian K, Szabo A, Ivanyi B, Gonczol E. Chlamydia pneumoniae in atherosclerotic middle cerebral artery. Stroke. 2001;32:1973-1976.
72. Johnston SC, Messina LM, Browner WS, Lawton MT, Morris C, Dean D. C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke. 2001;32:2748-2752.
73. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis. 1997;176:292-295.
74. Apfalter P, Loidl M, Nadrchal R, Makristathis A, Rotter M, Bergmann M, Polterauer P, Hirshl AM. Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens. Eur J Clin Microbiol Infect Dis. 2000;19:305-308.
75. Valassina M, Miglorini L, Sansoni A, Sani G, Corsaro D, Cusi MG, Valensin PE, Cellesi C. Search for Chlamydia pneumoniae genes and their expression in atherosclerotic plaques of carotid arteries. J Med Microbiol. 2001;50:228-232.
76. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis. 1998;177:725-729.
77. Godzik KL, O'Brien ER, Wang SK, Kuo CC. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol. 1995;33:2411-2414.
78. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, Gulba DC. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation. 1999;100:1369-1373.
79. Tiran A, Gruber HJ, Graier WF, Wagner AH, van Leeuwen EBM, Tiran B. Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-κB activation, cytokine expression, and bacterial development in human endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22:1075-1080.
80. Mosorin M, Surcel HM, Laurila A, Lehtinen M, Karttunen R, Juvonen J, Paavonen J, Marrison RP, Saikku P, Juvonen T. Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery. Arterioscler Thromb Vasc Biol. 2000;20:1061-1067.
81. Vainas T, Kurvers AJM, Mess WH, de Graaf R, Ezzahiri R, Tordoir JHM, Schurink GWH, Bruggeman CA, Kitslaar PJ. Chlamydia pneumoniae serology is associated with thrombosis-related but not with plaque-related microembolization during carotid endarterectomy. Stroke. 2002;33:1249-1254.
82. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang SP, Szklo M. Past infection by Chlamydia pneumoniae strain TW AR and asymptomatic carotid atherosclerosis. Am J Med. 1993;95:499-504.
83. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Hafner G, Pfeifer U, Meyer J. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? Stroke. 2000;31:2127-2133.
84. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation. 2000;102:833-839.
85. Schmidt C, Hulthe J, Wikstrand J, Gnarpe H, Gnarpe J, Agewall S, Fagerberg B. Chlamydia pneumoniae seropositivity is associated with carotid artery intima-media thickness. Stroke. 2000;31:1526-1531.
86. Markus HS, Sitzer M, Carrington D, Mendall MA, Steinmetz H. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation. 1999;100:832-837.
87. Coles KA, Plant AJ, Riley TV, Smith DW, McQuillan BM, Thompson PL. Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis. Am J Cardiol. 1999;84:825-828.
88. Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity. Circulation. 2001;103:1390-1395.
89. Wimmer ML, Sandmann-Strupp R, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. Stroke. 1996;27: 2207-2210.
90. Cook PJ, Honeybourne D, Lip GYH, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke. 1998;29:404-410.
91. Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2000;31:1521-1525.
92. Madre JG, Garcia JL, Gonzalez RC, Montero JM, Paniagua EB, Escribano JR, Martinez JD, Cenjor RF. Association between seropositivity to Chlamydia pneumoniae and acute ischaemic stroke. Eur J Neurol. 2002;9:303-306.
93. Heuschmann PU, Neureiter D, Gesslein M, Craiovan B, Maass M, Faller G, Beck G, Neundörfer B, Kolominsky-Rabas PL. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study. Stroke. 2001;32:2253-2258.
94. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Stroke. 1999;30: 299-305.
95. Glader CA, Stegmayr B, Boman J, Stenlund H, Weinehall L, Hallmans G, Dahlen GH. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions: results from a nested case control study in Northern Sweden. Stroke. 1999;30: 2013-2018.
96. Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med. 1999;131:573-577.
97. Tarnacka B, Gromadzka G, Czlonkowska A. Increased circulating immune complexes in acute stroke: the triggering role of Chlamydia pneumoniae and cytomegalovirus. Stroke. 2002;33:936-940.
98. Freidank HM, Lux A, Dern P. Meyer-König U, Els T. Chlamydia pneumoniae DNA in peripheral venous blood samples from patients with carotid artery stenosis. Eur J Microbiol Infect Dis. 2002;21:60-62.
99. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35:48-52.
100. Laitinen K, Laurila A, Pyhälä L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aorta of rabbits. Infect Immun. 1997;65:4832-4835.
101. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97: 633-636.
102. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein (Apo E)-deficient mice. J Infect Dis. 1999;180:238-241.
103. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA. 1999;281: 427-431.
104. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, of doxycycline. Emerg Infect Dis. 1999;5:281-284.
105. Gupta S, Leatham EW, Carrington D. Mendall MA, Kaski JC, Camm J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
106. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404-407.
107. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, Vuorinen-Markkola H, Nieminen MS, for the Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation. 2002;105:1555-1560.
108. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infarction With Chlamydia (ACADEMIC) study. Circulation. 1999;99:1540-1547.
109. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS study. Eur Heart J. 1999;20:121-127.
110. Melissano G, Blasi F, Esposito G, Tarsia P, Dordoni L, Arosio C, Tshomba Y, Fagetti L, Allegra L, Chiesa R. Chlamydia pneumoniae eradication from carotid plaques: results of an open, randomized study. Eur J Vasc Endovasc Surg. 1999;18:355-359.
111. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, Solbach W, Maass M. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001;103: 351-356.
112. Danesh J. Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies Am Heart J. 1999;138:S434-S437.
113. Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M. Prospective relations between Helicobacter pylori infection, coronary heart disease and stroke in middle aged men. Heart. 1996;75:568-572.
114. Markus HS, Mendall MA. Helicobacter pylori infection: a risk factor for ischaemic cerebrovascular disease and carotid atheroma. J Neurol Neurosurg Psychiatry. 1998;64:104-107.
115. Grau AJ, Buggle F, Lichy C, Brandt T, Becher H, Rudi J. Helicobacter pylori infection as an independent risk factor for cerebral ischemia of atherothrombotic origin. J Neurol Sci. 2001;186:1-5.
116. Ponzetto A, Marchet A, Pellicano R, Lovera N, Chianale G, Nobili M, Rizzetto M, Cerrato P. Association of Helicobacter pylori infection with ischemic stroke of non-cardiac origin: the BAT.MA.N. Project study. Hepatogastroenterology. 2002;49:631-634.
117. Pietroiusti A, Diomedi M, Silvestrini M, Cupini LM, Luzzi I, Gomez-Miguel MJ, Bergamaschi A, Magrini A, Carrabs T, Vellini M, Galante A. Cytotoxin-associated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation. 2002;106:580-584.
118. Markus HS, Risley P, Mendall MA, Steinmetz H, Sitzer M. Helicobacter pylori infection, the cytotoxin gene A strain, and carotid artery intima-media thickness. J Cardiovasc Risk. 2002;9:1-6.
119. Franceschi F, Sepulveda AR, Gasbarrini A, Pola P, Silveri NG, Dasbarrini G, Graham DY, Genta RM. Cross-reactivity of anti-CAGa anti-bodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation. 2002;106:430-434.
120. Farsak B, Yildirir A, Akyon Y, Pinar A, Oc M, Boke E, Kes S, Tokgozoglu L. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol. 2000;38:4408-4411.
121. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke. 2001;32:385-391.
122. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 1996;348:567-572.
123. Grau AJ, Buggle F, Ziegler C, Schwarz W, Meuser J, Tasman AJ, Buhler A, Benesch C, Becher H, Hacke W. Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke. 1997;28:1724-1729.
124. Lockhart PB. The risk for endocarditis in dental practice. Periodontology. 2000;23:127-35.
125. Chin B. Multiple infections in carotid atherosclerotic plaques. Am Heart J. 1999;138:S534-S546.
126. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol. 2000;71:1554-1560.
127. Armitage GC. Periodontal infections and cardiovascular disease: how strong is the association? Oral Dis. 2000;6:335-350.
128. Syrjänen J, Peltola J, Valtonen V, Iivanainen M, Kaste M, Huttunen JK. Dental infections in association with cerebral infarction in young and middle-aged men. J Intern Med. 1989;225:179-184.
129. Lösche WJ, Schork A, Terpenning MS, Chen YM, Kerr C, Dominguez BL. The relationship between dental disease and cerebral vascular accident in elderly United States veterans. Ann Periodontol. 1998;3:161-174.
130. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal disease and cardiovascular disease. J Periodontol. 1996;67:1123-1137.
131. Wu T, Trevisan M, Genco RJ, Dorn JP, Falkner KL, Sempos CT. Periodontal disease and risk of cerebrovascular disease: the First National Health and Nutrition Examination Survey and its follow-up study. Arch Intern Med. 2000;160:2749-2755.
132. Howell TH, Ridker PM, Ajani UA, Hennekens CH, Christen WG. Periodontal disease and risk of subsequent cardiovascular disease in U. S. male physicians. J Am Coll Cardiol. 2001;37:445-450.
133. Benditt EP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A. 1983;80:6386-6389.
134. Nicholson AC, Hajjar DP. Herpesviruses and thrombosis: activation of coagulation on the endothelium. Clin Chim Acta. 1999;286:23-29.
135. Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW, Szklo M. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation. 1996;94:922-927.
136. Saetta A, Fanourakis G, Agapitos E, Davaris PS. Atherosclerosis of the carotid artery: absence of evidence for CMV involvement in atheroma formation. Cardiovasc Pathol. 2000;9:181-183.
137. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation. 1998;98:2796-2799.
138. Zhou YF, Shou M, Guetta E, Guzman R, Unger EF, Yu ZX, Zhang J, Finkel T, Epstein SE. Cytomegalovirus infection in rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation. 1999;100:1569-1575.
139. Zhu J, Quyyumi AA, Norman JE, Costello R, Csako G, Epstein SE. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis. 2000;182:1583-1587.
140. Del Brutto OH. Infections and stroke. In: Ginsberg MD, Bogousslavsky J, eds. Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. Vol II. Malden, Mass: Blackwell Science; 1998:1639-1640.
141. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, Schlumberger W, Meyer J. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105:15-21.
142. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation. 2002;106:164-166.
143. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, Willeit J. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation. 2001;103:1064-1070.
144. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation. 1999;100:e20-e28.
145. Zhu J, Quyyumi AA, Norman JE, Csako G, Epstein SE. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation, as reflected by elevated C-reactive protein levels. J Am Coll Cardiol. 1999;34:1738-1743.
146. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513-520.
147. Xu Q, Schett G, Perschinka H, Mayr M, Egger G, Oberhollenzer F, Willeit J, Kiechl S, Wick G. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation. 2000;102:14-20.
148. Lourbakos A, Yuan YP, Jenkins AL, Travis J, Andrade-Gordon P, Santulli R, Potempa J, Pike RN. Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait of microbial pathogenicity. Blood. 2001;97: 3790-3797.
149. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:2910-2913.
150. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.
151. Wannamethee SG, Whincup PH, Shaper G, Walker M. Influence of fathers' social class on cardiovascular disease in middle-aged men. Lancet. 1996;348:1259-1263.
152. Prentice RL, Szatrowski TP, Kato H, Mason MW. Leukocyte counts and cerebrovascular disease. J Chron Dis. 1982;35:703-714.
153. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leukocytes and the risk of ischemic diseases. JAMA. 1987;257: 2318-2324.
154. Gillum RF, Ingram DD, Makuc DM. White blood cell count and stroke incidence and death: the NHANES I epidemiologic follow-up study. Am J Epidemiol. 1994;139:894-902.
155. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, of leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
156. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
157. Beamer NB, Coull BM, Clark WM, Briley DP, Wynn M, Sexton G. Persistent inflammatory response in stroke survivors. Neurology. 1998;50:1722-1728.
158. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
159. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study. Stroke. 2001;32:2575-2579.
160. Torzewski J, Torzewski M, Bowyer DE, Frohlick M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
161. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. A rterioscler Thromb Vasc Biol. 2000;20:1047-1051.
162. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke. 1999;30:981-985.
163. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001;32:917-924.
164. Di Napoli M, Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke. 2002;33:1763-1771.
165. Tohgi H, Konno S, Takahashi S, Koizumi D, Kondo R, Takahashi H. Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thromb Res. 2000;100:373-379.
166. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
167. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in longterm follow-up of prospective studies. Am J Epidemiol. 1999;150:341-353.
168. Marie P. Hémiplégie cérébrale infantile et maladies infectieuses. Le Progrès Médical. 1885;13:167-169.
169. Freud S. Die infantile Cerebrallähmung. In: Nothnagel H, ed. Specielle Pathologie 9, Teil 3 (I. Hälfte). Wien, Austria: Holder; 1897:1-327.
170. Syrjänen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged subjects. BMJ. 1988;296:1156-1160.
171. Syrjänen J, Valtonen VV, Iivanainen M, Hovi T, Malkamäki M, Mäkelä PH. Association between cerebral infarction and increased serum bacterial antibody levels in young adults. Acta Neurol Scand. 1986;73: 273-278.
172. Grau AJ, Buggle F, Heindl S, Steichen-Wiehn C, Banerjee T, Maiwald M, Rohlfs M, Suhr H, Fiehn W, Becher H. Recent infection as a risk factor for cerebrovascular ischemia. Stroke. 1995;26:373-379.
173. Grau AJ, Buggle F, Becher H, Zimmermann E, Spiel M, Fent T, Maiwald M, Werle E, Zorn M, Hengel H, Hacke W. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. Neurology. 1998;50:196-203.
174. Bova IY, Bornstein NM, Korczyn AD. Acute infection as a risk factor for ischemic stroke. Stroke. 1996;27:2204-2206.
175. Macko RF, Ameriso SF, Barndt R, Clough W, Weiner JM, Fisher M. Precipitants of brain infarction: roles of preceding infection/inflammation and recent psychological stress. Stroke. 1996;27:1999-2004.
176. Grau AJ, Buggle F, Steichen-Wiehn C, Heindl S, Banerjee T, Seitz R, Winter R, Forsting M, Werle E, Bode C. Clinical and biochemical analysis in infection-associated stroke. Stroke. 1995;26:1520-1526.
177. Grau AJ, Brandt T, Buggle F, Orberk E, Mytilineos J, Werle E, Conradt C, Krause M, Winter R, Hacke W. Association of cervical artetry dissection with recent infection. Arch Neurol. 1999;56:851-856.
178. Macko RF, Ameriso SF, Gruber A, Griffin JH, Fernandez JA, Barndt R, Quismorio FP Jr, Weiner JM, Fisher M. Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke. 1996;27: 2005-2011.
179. Ameriso SF, Wong VLY, Quismorio FP Jr, Fisher M. Immunohematologic characteristics of infection-associated cerebral infarction. Stroke. 1991;22:1004-1009.
180. Martinez MA, Pena JM, Fernandez A, Jimenez M, Juarez S, Madero R, Vazquez JJ. Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-α. Crit Care Med. 1999;27:1303-1308.
181. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res. 1989;53:231-241.
182. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989;73:159-165.
183. Hart RG, Foster JW, Luther MF, Kanter MC. Stroke in infective endocarditis. Stroke. 1990;21:695-700.
184. Gustafsson C, Blombäck M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990;21:47-51.
185. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-2891.
186. Richardson SGN, Matthews KB, Cruickshank JK, Geddes AM, Stuart J. Coagulation activation and hyperviscosity in infection. Br J Haematol. 1979;42:469-480.
187. Ogata K, Yagawa K, Hayashi S, Ogino H, Miyagawa Y, Masayuki M, Ichinose Y, Koga T. Thrombosis-inducing activity in plasma of patients with acute respiratory tract infection disappears after treatment. Respiration. 1991;58:176-180.
188. Lavallee P, Perchaud V, Gautier-Bertrand M, Grabli D, Amarenco P. Association between influenza vaccination and reduced risk of brain infarction. Stroke. 2002;33:513-518.
189. Hegele RA, Ban MR, Anderson CM, Spence JD. Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area. J Invest Med. 2000;48:198-202.
190. Lozano ML, Gonzalez-Conejero R, Corral J, Rivera J, Iniesta JA, Martinez C, Vicente V. Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. Br J Haematol. 2001;115:969-976.
191. Herrmann SM, Funke-Kaiser H, Schmidt-Petersen K, Nicaud V, Gautier-Bertrand M, Evans A, Kee F, Arveiler D, Morrison C, Orzechowski HD, et al. Characterization of polymorphic structure of cathepsin G gene: role in cardiovascular and cerebrovascular diseases. Arterioscler Thromb Vasc Biol. 2001;21:1538-1543.
192. 279→Phe) is a genetic risk factor. Stroke. 1997;28:2417-2420.
193. Unkelbach K, Gardemann A, Kostrzewa M, Philipp M, Tillmanns H, Haberbosch WA. New promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol. 1999;19:932-938.
194. Hubacek JA, Pit'ha J, Skodova Z, Stanek V, Poledne R. C(-260)→T polymorphism in the promotor of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation. 1999;99:3218-3220.
195. Ito D, Murata M, Tanashi N, Sato H, Sonoda A, Saito I, Watanabe K, Fukuuchi Y. Polymorphism in the promotor of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke. 2000;31: 2661-2664.
196. Zee RY, Bates D, Ridker PM. A prospective evaluation of the CD14 and CD18 gene polymorphisms and risk of stroke. Stroke. 2002;33: 892-895.
197. Lichy C, Meiser H, Grond-Ginsbach C, Buggle F, Dörfer C, Grau A. Lipopolysaccharide receptor CD14 polymorphism and risk of stroke in a South-German population. J Neurol. 2002;249:821-823.
198. Grau AJ, Aulmann M, Lichy C, Meiser H, Buggle F, Brandt T, Grond-Ginsbach C. Increased cytokine release by leucocytes in survivors of stroke at young age. Eur J Clin Invest. 2001;31:999-1006.
199. Revilla M, Obach V, Cervera A, Dávalos A, Castillo J, Chamorro A. A-174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett. 2002;324:29-32.
200. Velasco JA. After 4S, CARE and LIPID-is evidence-based medicine being practised? Atherosclerosis. 1999;147(suppl 1):S39-S44.
201. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, et al, for the CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation. 1999;99:216-223.
202. Hess DC, Demchuk AM, Brass LM, Yatsu FM. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology. 2000;54:790-796.
203. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E, for the CARE Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98: 839-844.
204. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577-581.
205. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the CARE Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-235.
206. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
207. Romano M, Mezzetti A, Marulli, Ciabattoni G, Febo F, Di Ienno S, Roccaforte S, Vignieri S, Nubile G, Milani M, Davi G. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Invest Med. 2000;48:183-189.
208. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353:983-984.
209. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocomo M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 2000;80:1095-1100.
210. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, Egido J. Atorvastatin reduces NF-κB acivation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253-261.
211. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G, Cottens S, Weitz-Schmidt G, Hommel U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol. 1999;292:1-9.
212. Inoue I, Goto S, Mizotani, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of m-RNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor a (PPARa) in primary endothelial cells. Life Sci. 2000;67:863-876.
213. Dupuis J, Tardif J-C, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary sundromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 1999;99:3227-3233.
214. Weissberg P. Mechanisms modifying atherosclerotic disease: from lipids to vascular biology. Atherosclerosis. 1999;147(suppl 1):S3-S10.
215. Kothe H, Dalhoff K, Rupp J, Müller A, Kreutzer J, Maass M, Katus HA. Hydroxylmethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 2000;101:1760-1763.
216. Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol. 1998;153:1825-1837.